Compliance with Ethical Standards

Immune checkpoint inhibitors have recently received the U.S. Food and Drug Administration and European Medical Agency approval as first and second-line treatment for non-small cell lung cancer (NSCLC) [1 –3]

Source: Seminars in Arthritis and Rheumatism - January 6, 2018 Category: Rheumatology Authors: Marco Filetti, Elisabetta Anselmi, Serena Macrini, Francesco Rizzo, Daniela Iacono, Raffaele Giusti, Paolo Machetti Source Type: research